CoChat
Sign Up
Cited by 161

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., Home, P., Kahn, S. E., McLellan, J. H., Perera, R., Plüddemann, A., Ramachandran, A., Roberts, N. W., Rose, P. W., Schweizer, A., Viberti, G., Holman, R. R.·2012·Diabetologia
DOI 10.1007/s00125-012-2653-7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-012-2653-7

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 13 references

Research works printed but not linked: 33

  1. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167 · DOI
  2. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305 · DOI · Paper page
  3. Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777 · DOI · Paper page
  4. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625 · DOI · Paper page
  5. Bowker SL, Yasui Y, Veugelers P, Johnson JA (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631–1637 · DOI
  6. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11:20 · DOI · Paper page
  7. Ruiter R, Visser LE, van Herk-Sukel MPP et al (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35:119–124 · DOI
  8. DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451–1461 · DOI · Paper page
  9. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299–304 · DOI
  10. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q (2011) Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 58:482–490 · DOI
  11. Bao B, Wang Z, Ali S et al (2012) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 5:355–364 · DOI
  12. Arkadieva AV, Mamonov AA, Popovich IG, Anisimov VN, Mikhelson VM, Spivak IM (2011) Metformin slows down ageing processes at the cellular level in SHR mice. Cell Tissue Biol 5:151–159 · DOI
  13. UK Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865 · DOI · Paper page
  14. Moghetti P, Castello R, Negri C et al (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139–146 · DOI · Paper page
  15. Lefebvre C, Manheimer E, Glanville J (2011) Chapter 6: Searching for studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.Cochrane-handbook.org
  16. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, Art. no: CD002967, doi 10.1002/14651858.CD002967.pub4 · DOI
  17. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135 · DOI · Paper page
  18. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV (2005) Comparative outcomes study of metformin intervention versus conventional approach: the COSMIC Approach Study. Diabetes Care 28:539–543 · DOI
  19. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297 · DOI · Paper page
  20. Pfützner A, Paz-Pacheco E, Allen E, Frederich R, Chen R (2011) Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 13:567–576 · DOI
  21. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53:1838–1845 · DOI
  22. Turner RC, Holman RR (1999) Metformin and risk of cardiovascular disease. Cardiology 91:203–204 · DOI
  23. Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54:25–31 · DOI
  24. Ferrara A, Lewis JD, Quesenberry CP Jr et al (2011) Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34:923–929 · DOI
  25. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499–2506 · DOI
  26. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 281:2005–2012 · DOI · Paper page
  27. Schneider MB, Matsuzaki H, Haorah J et al (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120:1263–1270 · DOI
  28. Muti P, Berrino F, Krogh V et al (2009) Metformin, diet and breast cancer: an avenue for chemoprevention. Cell Cycle 8:2661 · DOI
  29. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V (2003) Six-year results from the Early Diabetes Intervention Trial. Diabetic Medicine 20:15, Abstract
  30. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068–6076 · DOI
  31. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, QUARTET Study Group (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141–147 · DOI · Paper page
  32. Schweizer A, Couturier A, Foley JE, Dejager S (2007) Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 24:955–961 · DOI
  33. Williams-Herman D, Johnson J, Teng R et al (2010) Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 12:442–451 · DOI

Cited by

Sorted by citations

See all 161

Metadata

Authors
Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., Home, P., Kahn, S. E., McLellan, J. H., Perera, R., Plüddemann, A., Ramachandran, A., Roberts, N. W., Rose, P. W., Schweizer, A., Viberti, G., & Holman, R. R.
Venue
Diabetologia
Publisher
Springer Science and Business Media LLC
Published
2012-08-10
Volume
55
Issue
10
Pages
2593-2603
ISSN
  • 0012-186X
  • 1432-0428
DOI
10.1007/s00125-012-2653-7
Cited by
161
References
13
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review